Stay updated on Amgen Press Releases

Sign up to get notified when there's something new on the Amgen Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Amgen Press Releases page

  1. Check
    2 days ago
    Change Detected
    Summary
    Amgen has announced several significant updates, including the availability of Otezla® for pediatric plaque psoriasis, upcoming presentations at major healthcare conferences, and the approval of Blincyto® for a specific type of leukemia.
    Difference
    100%
    Check dated 2024-09-04T03:47:36.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    Amgen has made several significant announcements, including the approval of Blincyto® for B-ALL and the first quarter 2024 financial results, while notable deletions include the second quarter 2024 financial results and the announcement of the third quarter dividend.
    Difference
    100%
    Check dated 2024-08-20T23:48:43.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    Amgen has reported its second quarter 2024 financial results and announced a third quarter dividend, along with a webcast for the financial results.
    Difference
    38%
    Check dated 2024-08-06T21:35:40.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    In June 2024, the FDA approved Blincyto® for treating CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, while Amgen announced positive Phase 3 trial results for Uplizna® and plans to present at several major healthcare conferences.
    Difference
    100%
    Check dated 2024-07-30T21:34:49.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Summary
    Amgen has made significant advancements in oncology and rheumatology, including the FDA approval of Blincyto for B-ALL and Imdelltra for small cell lung cancer, alongside positive trial results for Uplizna in IgG4-RD.
    Difference
    100%
    Check dated 2024-07-27T18:14:35.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Summary
    In June 2024, the FDA approved Blincyto® for treating CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, while Amgen announced positive results for Uplizna® in treating IgG4-related disease and plans to present innovative rheumatology research at EULAR 2024.
    Difference
    100%
    Check dated 2024-07-26T17:00:59.000Z thumbnail image

Stay in the know with updates to Amgen Press Releases

Enter your email address, and we'll notify you when there's something new on the Amgen Press Releases page.